Interested why Kollidon® 12 PF / Kollidon® 17 PF are particularly suitable for parenteral applications?

One-pager on the BASF PVP-based solubilizers — BASF Kollidon® 12 PF / Kollidon® 17 PF One-pager

Did you know that Kollidon® 12 PF and Kollidon® 17 PF are highly suitable for injectable formulations?
Kollidon® 12 PF/ Kollidon® 17 PF low molecular weight make them particularly suitable for parenteral
applications. Additionally, they are used as matrix formers in solid dispersions, highly effective
stabilizers in liquid dispersions, as well as functional pore formers in solid oral dosage forms.

The main product benefits are:

Amorphous – state Characterization and Dissolution Behaviour of Efavirenz – Tocopheryl Polyethylene Glycol Succinate (TPGS)-1000 Solid Dispersions

Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: Exploration of lipophilic counterions and in vitro-in vivo evaluation

Resomer® and Lactel® Portfolio of Excipients for Parenteral Controlled Release by Evonik

Formation of water-soluble complexes with APIs inhibits crystallization
Excellent lyophilization agents and suspension stabilizers
Rapid renal elimination without polymer accumulation in the body due to low molecular weight
Proven tolerability
Endotoxin-controlled
Complies to the Povidone monographs of Ph.Eur., USP-NF, and JP
FDA IID listed
Innovative PeroXeal™ packaging concept limiting peroxide formation – a unique combination
of an oxygen impermeable inliner packaging and a filling process under inert conditions

Here you can download the one-pager: 314036_BASF_Pharma_Kollidon_12_17_PF_OnPager_A4_AS (1)